Arrowhead Clinic is excited to introduce a new range of services that focus on car accident injuries, providing patients in ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Arrowhead Clinic in Garden City is excited to announce a new resource available on their WordPress site detailing advanced ...

Preliminary data are expected this year for a Phase 1/2 clinical trial testing the investigational therapy SRP-1003 in DM1.

We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...

Sarepta stock has been in free fall since safety issues derailed Elevidys, a gene therapy analysts had expected to achieve ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...